Cancer News and Research

Latest Cancer News and Research

UVA exposure at early age does not cause melanoma

Early life exposure to ultraviolet A light does not cause melanoma in a fish model that previously made that connection, scientists from The University of Texas MD Anderson Cancer Center reported today in the online Early Edition of the Proceedings of the National Academy of Sciences.

5 May 2010

Akela Pharma, PharmaForm file second bi-weekly Default Status Report under NP 12-203

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, are providing their second bi-weekly Default Status Report under National Policy 12-203 - Cease Trade Orders for Continuous Disclosure Defaults ("NP 12-203").

5 May 2010

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Rates of colorectal cancer screening vary by race and ethnicity as well as method, according to data being presented at Digestive Disease Week- 2010. Scientists examine data on minority and older populations as well as utilization rates of virtual and optical colonoscopies to better understand adherence to recommended screening guidelines.

5 May 2010

Non-compliance, NSAIDs use inhibit clinical benefit of aspirin

Charles H. Hennekens, M.D., the first Sir Richard Doll Research Professor in the Charles E. Schmidt College of Biomedical Science at Florida Atlantic University, was the first to demonstrate that aspirin prevents a first heart attack based on his landmark Physicians Health Study (PHS).

5 May 2010

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1). Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%.

5 May 2010

Australian researchers show positive effect of growth hormone on athletic performance

Australian researchers have published the results of a study, for the first time showing a positive effect of growth hormone on athletic performance.

5 May 2010

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Particular parvoviruses normally infect rodents, but they are also infectious for human cells. However, they do not cause any disease symptoms in humans. Most importantly, these viruses have an astonishing property: They kill infected tumors cells without causing any damage to healthy tissue.

5 May 2010

Deloitte Survey: Consumers still profess to know very little about health care system in the U.S.

Following widespread media coverage of health care reform, political debates and legislative initiatives over the past year, consumers still profess to know very little about the health care system in the United States, according to the 3rd Annual Deloitte Center for Health Solutions Survey of Health Care Consumers.

5 May 2010

High doses of antioxidant nutritional supplements may predispose cells to develop cancer

High doses of antioxidant nutritional supplements, such as vitamins C and E, can increase genetic abnormalities in cells, which may predispose supplement-takers to developing cancer, according to a new study from the Cedars-Sinai Heart Institute.

5 May 2010

TeleHealth Services announces launch of High Blood Pressure and Stroke Awareness Campaign

TeleHealth Services, the nation's leading provider of interactive patient education systems and healthcare grade televisions for hospitals, today announced the launch of the High Blood Pressure and Stroke Awareness Campaign in support of National Stroke Awareness month, which takes place in May every year.

5 May 2010

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

Anavex Life Sciences Corp. is pleased to report promising results from animal studies with ANAVEX 2-73, the company's lead compound for the treatment and modification of Alzheimer's disease.

5 May 2010

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

S*BIO Pte Ltd and Onyx Pharmaceuticals, Inc. today announced the expansion of their development collaboration and option and license commercialization agreement for S*BIO's novel JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively. The expanded agreement builds upon the development and commercialization collaboration between the two companies announced in January 2009.

5 May 2010

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Romark Laboratories announced results from its STEALTH C-3 clinical trial, a phase 2 clinical study of nitazoxanide in treatment-naive patients with genotype 1 chronic hepatitis C. Study results were presented this afternoon as an oral communication at a late breaking forum of the American Gastroenterological Association Institute during Digestive Disease Week 2010 in New Orleans, Louisiana.

5 May 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

QRxPharma announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application submission with the United States Food and Drug Administration, this "combination rule" study compared the efficacy and safety profiles of MoxDuo IR against component doses of morphine and oxycodone alone for the management of moderate to severe post-operative pain following bunionectomy surgery.

5 May 2010

Health IT Roundup: Many obstacles, much promise

The Boston Globe: There is a lingering "professional resistance to electronic records systems that computerization advocates say threatens the goals of the new health care overhaul law. These advocates argue that using computers to track what care patients receive, for instance, is vital to deciding what medications and treatments work best."

5 May 2010

Latest version of Phase Forward CDC released

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced the latest version of the Phase Forward Clinical Development Center, a centralized solution for integrating, managing and analyzing clinical information.

5 May 2010

Study: Flaxseed diet reduces ovarian cancer, increases survival rates

In the race to find answers about ovarian cancer, researchers now have something to cluck about. For five years, University of Illinois researchers have been using the chicken as a model to study this deadly disease and have recently discovered that a diet enriched with flaxseed decreases severity of ovarian cancer and increases survival in hens.

5 May 2010

Clinical preventive services can reduce death rates

"Prevention is the best medicine," the saying goes. According to a new study, increasing the use of that medicine could prevent a significant number of adult deaths annually.

5 May 2010

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Myriad Genetics, Inc. today reported financial results for the third fiscal quarter and the nine-month period ended March 31, 2010.

5 May 2010

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Patients who have gastric cancer surgery followed by chemotherapy have an associated decreased risk of death and improved disease-free survival compared to patients who have surgery alone, according to an analysis of previous studies, reported in the May 5 issue of JAMA.

5 May 2010

Cancer News and Research

Latest Cancer News and Research

UVA exposure at early age does not cause melanoma

Akela Pharma, PharmaForm file second bi-weekly Default Status Report under NP 12-203

Data shows rates of colorectal cancer screening vary by race, ethnicity and method

Non-compliance, NSAIDs use inhibit clinical benefit of aspirin

ChemoCentryx reports positive data with Traficet-EN in Crohn's disease trial

Australian researchers show positive effect of growth hormone on athletic performance

Study: Parvovirus therapy offers complete regression of malignant brain tumors

Deloitte Survey: Consumers still profess to know very little about health care system in the U.S.

High doses of antioxidant nutritional supplements may predispose cells to develop cancer

TeleHealth Services announces launch of High Blood Pressure and Stroke Awareness Campaign

Anavex reports promising results from ANAVEX 2-73 Alzheimer's disease compound in animal studies

S*BIO, Onyx Pharmaceuticals expand development, commercialization collaboration for JAK2 Inhibitors

Results from STEALTH C-3 clinical trial of nitazoxanide presented at DDW 2010

Additional pivotal Phase 3 trial data for MoxDuo IR released

Health IT Roundup: Many obstacles, much promise

Latest version of Phase Forward CDC released

Study: Flaxseed diet reduces ovarian cancer, increases survival rates

Clinical preventive services can reduce death rates

Myriad Genetics' third-quarter fiscal 2010 revenues increase 5% to $90.8M

Adjuvant chemotherapy after gastric cancer procedure may reduce mortality

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in